Search
Clinician Ordering Portal
Frequently Asked Questions
The DecisionDx-UM test measures the gene expression profile (GEP), or molecular signature, of a patient’s primary tumor to determine the risk that the tumor will spread (metastasize) from the eye to other parts of the body. The test is validated for expression profile (GEP), or molecular signature, of a patient’s primary tumor to determine the risk that the tumor will spread (metastasize) from the eye to other parts of the body. The test is validated for use on both fine needle aspirate biopsy (FNAB) tissue and formalin-fixed, paraffin-embedded (FFPE) tissue. Test results are typically reported within two weeks of receiving the biopsy sample from the treating physician.
DecisionDx-UM is Castle’s 15-gene expression profile (GEP) test that uses tumor biology to predict a patient’s individual risk of cancer metastasizing (spreading to other parts of the body). DecisionDx-UM is the standard of care in the management of uveal melanoma in the majority of ocular oncology practices in the United States. Since its availability in 2009, over 15,000 patients have been clinically tested with DecisionDx-UM.
Castle offers three tests for patients with uveal melanoma that can all be run from a single tumor biopsy sample: DecisionDx-UM (standard of care-adopted by ~90% of ocular oncology centers); DecisionDx-PRAME (optional supplemental test); DecisionDx-UMSeq (optional supplemental test). The DecisionDx-UM test is the most extensively validated prognostic method for uveal melanoma and is considered standard of care due to its wide acceptance by physicians and its inclusion in national guidelines.
Please call our customer service staff at 866-788-9007 or email.